Clinical trial · Interventional
Adenosine Triphosphate in Treating Patients With Advanced Solid Tumors
A Phase I Study And Pharmacokinetics Of Adenosine 5'- Triphosphate (ATP) When Administered By Intravenous Infusion On A Multiple Weekly Dose Schedule To Patients With Advanced Malignancies (Solid Tumors)
NCT00014248CI-TRIAL-00009743completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Adenosine triphosphate may decrease weight loss and improve muscle strength in patients with advanced solid tumors. PURPOSE: Phase I trial to study the effectiveness of adenosine triphosphate in controlling loss of weight and loss of muscle mass in patients who have advanced solid tumors.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cachexia | — | UNRESOLVED | — |
| Unspecified Adult Solid Tumor, Protocol Specific | Adult Solid Neoplasm | ALIAS | 0.85 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| adenosine triphosphate | Drug | — | UNRESOLVED |
| quality-of-life assessment | Procedure | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed advanced solid tumor that is not curable by conventional therapy * Brain metastases allowed if adequately controlled with radiotherapy PATIENT CHARACTERISTICS: Age: * Over 18 Performance status: * Karnofsky 60-100% Life expectancy: * At least 12 weeks Hematopoietic: * WBC at least 3,500/mm\^3 * Absolute neutrophil count at least 2,000/mm\^3 * Platelet count at least 100,000/mm\^3 Hepatic: * SGOT and SGPT no greater than 3 times normal * Bilirubin no greater than 2.0 mg/dL Renal: * Creatinine no greater than 1.5 mg/dL * Creatinine clearance greater than 60 mL/min * BUN no greater than 25 mg/dL Cardiovascular: * Adequate cardiovascular function * No congestive heart failure (New York Heart Association class III or IV heart disease) * No angina pectoris AND/OR * No significant arrhythmia * No myocardial infarction within the past 6 months * No clinically significant ischemic cardiac disease currently under treatment * No clinically significant conduction system disease in the absence of a pacemaker (e.g., sick sinus syndrome, or second or third degree atrioventricular block) Pulmonary: * Adequate pulmonary function * No clinical evidence of acute chronic obstructive pulmonary disease * FEV1 at least 50% predicted * Arterial oxygen tension at least 90% by pulse oximetry and on breathing room air * No asthma OR * No evidence of more than 20% reversibility in FEV1 with albuterol therapy Other: * Not pregnant or nursing * Fertile patients must use effective contraception * No history of severe adverse reaction to adenosine * No uncontrolled medical illness * No average daily pain scores of at least 5 on a simple Visual Analogue Self pain assessment (0-10) scale PRIOR CONCURRENT THERAPY: Biologic therapy: * Not specified Chemotherapy: * At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered Endocrine therapy: * Not specified Radiotherapy: * See Disease Characteristics * At least 3 weeks since prior radiotherapy and recovered Surgery: * Not specified Other: * At least 30 days since prior investigational therapy * At least 14 days since prior long-term theophylline, dipyridamole, or dipyridamole/aspirin therapy * No concurrent long-term theophylline, dipyridamole, or dipyridamole/aspirin therapy * No concurrent maintenance anti-anginal drug therapy
References
Publications (0)
Data not yet available
No reference posted for this study.